GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » ROIC %

Ocumension Therapeutics (HKSE:01477) ROIC % : -17.18% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Ocumension Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -17.18%.

As of today (2024-06-05), Ocumension Therapeutics's WACC % is 12.06%. Ocumension Therapeutics's ROIC % is -20.39% (calculated using TTM income statement data). Ocumension Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Ocumension Therapeutics ROIC % Historical Data

The historical data trend for Ocumension Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics ROIC % Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial -1,017.69 -184.85 -38.78 -26.57 -19.81

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -33.19 -27.58 -27.21 -24.72 -17.18

Competitive Comparison of Ocumension Therapeutics's ROIC %

For the Biotechnology subindustry, Ocumension Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's ROIC % falls into.



Ocumension Therapeutics ROIC % Calculation

Ocumension Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-438.977 * ( 1 - -0.08% )/( (1929.902 + 2505.726)/ 2 )
=-439.3281816/2217.814
=-19.81 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3398.916 - 120.573 - ( 1438.828 - max(0, 276.558 - 1624.999+1438.828))
=1929.902

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3577.75 - 98.178 - ( 1147.922 - max(0, 344.851 - 1318.697+1147.922))
=2505.726

Ocumension Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-389.026 * ( 1 - -0.1% )/( (2028.407 + 2505.726)/ 2 )
=-389.415026/2267.0665
=-17.18 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3282.391 - 206.762 - ( 1111.223 - max(0, 233.824 - 1281.046+1111.223))
=2028.407

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3577.75 - 98.178 - ( 1147.922 - max(0, 344.851 - 1318.697+1147.922))
=2505.726

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumension Therapeutics  (HKSE:01477) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Ocumension Therapeutics's WACC % is 12.06%. Ocumension Therapeutics's ROIC % is -20.39% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Ocumension Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Liu Ye 2101 Beneficial owner
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Chen Ziqing 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Boyu Capital Fund Iv, L.p 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines